0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Comparative Efficacy of Colestipol and Clofibrate in Type IIa Hyperlipoproteinemia

Thomas J. Vecchio, MD; Christine V. Linden, MS; Martin J. O'Connell, PhD; Jill Heilman, MPH
Arch Intern Med. 1982;142(4):721-723. doi:10.1001/archinte.1982.00340170077016.
Text Size: A A A
Published online

• A multiclinic study was performed comparing colestipol hydrochloride, clofibrate, and placebo in 245 patients with type IIa hyperlipoproteinemia. Eighty-five subjects took colestipol hydrochloride in progressive doses of 15, 20, and 30 g/day; 87 took 2.0 g/day of clofibrate; and 73 took placebo over the six months of study. Colestipol lowered total cholesterol level 20.9% in comparison with clofibrate (14.6%) (statistically significant at months 3, 5, and 6), and lowered low-density lipoprotein cholesterol level 28.8% in comparison with clofibrate (14.8%) (significant at months 2, 4, and 6, all times measured). High-density lipoprotein cholesterol level remained unchanged in all groups. Clofibrate lowered total triglyceride levels 22.5%, compared with an increase of 12.5% in the colestipol group and 11.1% in the placebo group (significant at all time intervals). Colestipol was more effective than clofibrate in lowering the cholesterol fractions associated with increased cardiovascular risk.

(Arch Intern Med 1982;142:721-723)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();